TAGRISSO® (OSIMERTINIB) PLUS SAVOLITINIB REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 45% AND THE RISK OF DEATH BY 32% IN MET-DRIVEN EGFR-MUTATED LUNG CANCER AFTER PROGRESSION ON TAGRISSO

Reuters · 1d ago

Please log in to view news